Profusa To Merge With Privately Held, Commercial-Stage Health Diagnostics And Toxicology Testing Company; Profusa To Issue 19.99% Stake to The Company And Will Issue Convertible Prefs; Combined Entity Operate As Public Diagnostics Firm
Following the contemplated transaction, the combined company is expected to operate as a public diagnostics company with national CLIA-certified laboratories, recurring revenues from a diversified base of providers
Profusa is joining forces with another health-testing company to become one bigger public company. This means they'll have more labs and customers, so watch whether the combined company can actually make money and keep customers happy.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.